Medtronic announced its total worldwide revenue for the third quarter of fiscal year 2014 is $4.163 billion, up slightly from its revenue during the same period last year, $4.027 billion.
The company's worldwide spine revenue was $744 million, down from $753 million during the same period last year.
In the United States, Medtronic's total revenue amounted to $ 2.265 billion in the third quarter of FY 2014, whereas during the third quarter of FY 2013 yielded $2.171 billion. Medtronic's U.S. spine revenue was $517 million for Q3, down from $522 million during the same period last year.
The company's core spine business reported $631 million revenues during the third quarter, down from the previous quarter and the same time last year. It's bone morphogenic protein business grew $3 million from the last quarter—hitting $113 million in Q1—but continues to slump in the U.S. with revenue at $98 million, compared with $100 million during the same quarter last year.
Medtronic's U.S. surgical technologies revenue saw a spike to $241 million in Q3 of from $215 million over the same period last year. Revenue growth was driven by upgrades of the StealthStation S7 Surgical Navigation System and NIM ENT nerve monitoring capital equipment as well as U.S. sales of O-arm imaging capital equipment, among others.
More Articles on Devices:
Paradigm Spine, PDL BioPharma Enter Secured Debt Financing Agreement for $75M
Aurora Spine Receives FDA 510(k) Clearance for Titanium Plasma Spray Coated Spinal Fusion Implants
OrthAlign Signs Exclusive Distribution Agreement With Biomet Japan for KneeAlign